Eszopiclone 3 mg: Efficacy, Safety Monitoring, and Adjunctive Behavioral Therapy

Efficacy in Adults with Insomnia

Safety Monitoring

Integration with Behavioral Therapy

Eszopiclone Efficacy and Safety

Dosing and Efficacy

• The American Academy of Sleep Medicine recommends a 2 mg dose of eszopiclone, which reduces sleep latency by 10-14 minutes and wake after sleep onset by similar amounts compared to placebo 2
• The 3 mg dose of eszopiclone improves sleep efficiency by 5.61% and total sleep time by 28-57 minutes versus placebo 2, 3

Adverse Effects

• Eszopiclone is associated with an unpleasant/metallic taste in 17-26% of patients, somnolence in 8.8-9.1%, dry mouth in 6.6%, and dizziness in 9.8%, as reported by the American Academy of Sleep Medicine 2, 4
• Headache shows no difference from placebo across all doses of eszopiclone, according to the American Academy of Sleep Medicine 2, 4